Qualia Gluthathione+ 对血液谷胱甘肽水平的影响
This is a double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be assigned to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.
研究概览
地位
详细说明
Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation. Earlier versions of this record described the design as randomized. The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used. No other aspect of the study design, conduct, or analysis changed.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
Carlsbad、California、美国、92011
- Qualia Life Sciences
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria:
- Provide voluntary, written, informed consent to participate in the study
- Agree to provide a valid cell phone number and are willing to receive communications through text
- Can read and write English
- Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
- Willing to complete questionnaires, records, and diaries associated with the study.
- Healthy male and female participants aged 45-75 years
- Willing to go to a local blood draw location for a Whole Blood Total Glutathione measurement (baseline and Day 20)
- Willing to avoid starting new or stopping any existing dietary supplements throughout the study
Exclusion criteria:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
- Known food intolerances/allergy to any ingredients in the product
- Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
- Having had a significant cardiovascular event in the past 6 months
- Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
- On immunosuppressive therapy
- Adults lacking capacity to consent
- Active Smokers
- Diagnosed Diabetics
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Qualia Glutathione+ version 1
Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences |
Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences |
|
有源比较器:Qualia Glutathione+ version 2
Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences |
Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences |
|
安慰剂比较:Placebo
Rice flour placebo |
Rice flour |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Total Glutathione levels from baseline to Day 20
大体时间:0-20 days
|
To assess between-group differences in the change in blood Total Glutathione levels from baseline to Day 20 following supplementation with Qualia Glutathione version 1 versus placebo and Qualia Glutathione version 2 versus placebo |
0-20 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
between-group differences in blood Total Glutathione levels
大体时间:baseline to day 20
|
To assess the between-group differences in blood Total Glutathione levels from baseline to Day 20 following supplementation between Qualia Glutathione version 1 and Qualia Glutathione version 2. |
baseline to day 20
|
|
within-group differences in the change in blood Glutathione levels
大体时间:baseline to day 20
|
To assess within-group differences in the change in blood Glutathione levels |
baseline to day 20
|
|
Safety and Tolerability survey
大体时间:baseline to days 7, 14 and 20
|
To evaluate side effect profiles using a custom Safety and Tolerability survey. |
baseline to days 7, 14 and 20
|
|
PROMIS Global Health-10
大体时间:baseline to days 7, 14 and 20
|
The PROMIS® Global Health Scale v1.2 (also known as the PROMIS-GH or PROMIS-10) is a 10-item, non-disease-specific questionnaire for adults to assess general physical and mental health. It yields two main scores, a Global Physical Health (GPH) T-score and a Global Mental Health (GMH) T-score, derived from four items each, to understand overall health perceptions. The scale is widely translated and free for use in clinical and research settings.
|
baseline to days 7, 14 and 20
|
|
PROMIS Short Form v1.0 - Fatigue 10a
大体时间:baseline to days 7, 14 and 20
|
The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal rather than disease-specific. All assess fatigue over the past seven days. Raw Score Minimum and Maximum: 10-50 the lower the better |
baseline to days 7, 14 and 20
|
|
PROMIS Cognitive Function - Short Form 8a
大体时间:baseline to days 7, 14 and 20
|
The PROMIS Cognitive Function v2.0 - Short Form 8a is an 8-item self-report questionnaire designed to assess perceived cognitive function over the past seven days. It measures difficulties in areas such as forming thoughts, concentration, attention, thinking speed, memory, and the ability to shift between tasks. - Raw Score Minimum and Maximum: 8-40 - The higher the score, the better |
baseline to days 7, 14 and 20
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- QLS-019
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.